Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares

New York City-based Suvretta Capital sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) in Q3, trimming its position by about $35.78 million to roughly 10.48 million shares valued at $197.51 million as of September 30, making ARQT roughly a 5% position in the fund’s $3.91 billion 13F assets. Arcutis shares were trading at $30 on Nov. 13, up ~100% year-over-year; the company has TTM revenue of $317.93 million, a TTM net loss of $44.32 million and a $3.67 billion market cap. Management continues commercial execution with ZORYVE gaining prescriptions and regulatory progress (FDA accepted a pediatric sNDA with a June 29 target), so the sale reads as portfolio risk management after a dramatic re-rating rather than a loss of conviction.

Analysis

Market structure: Suvretta’s 1.1M-share trim is liquidity-management not a verdict — ARQT remains its largest holding at ~$197.5M, so flows are unlikely to force a prolonged price shock. The stock has re-rated (up ~100% Y/Y) which increases sensitivity to execution versus narrative; winners include well-positioned dermatology incumbents if ZORYVE adoption validates premium pricing, while small-cap peers face relative outflows.

Risk assessment: Key tail risks are a June 29 sNDA refusal or negative pediatric safety signals, slower-than-expected prescription growth, or gross-margin pressure from pricing/reimbursement — each could trigger 30–50% downside in quarters. Near-term (days–weeks) expect volatility around script data/earnings; medium-term (3–9 months) PDUFA and prescription cadence; long-term (1–3 years) depends on multi-indication commercialization and payer access.

Trade implications: Tactical longs should be event-driven and hedged: use defined-risk option structures around the June 29 sNDA date and scale on weakness to target buy zones (20% and 30% retracements). Consider pair trades (long ARQT / short XBI or a small-cap biotech basket) to isolate idiosyncratic execution risk. Liquidity is adequate for options strategies; cross-asset impact on rates/FX is negligible.

Contrarian angles: The market underestimates continued conviction — Suvretta’s trim signals risk management, not capitulation; institutional concentration can amplify both rallies and drops. Mispricing exists if prescription growth sustains >30% QoQ: upside could be >50% from current levels. Conversely, if payoff is binary (pediatric denial), downside will be compressed and fast — prepare for asymmetric outcomes.

Key Decisions for Investors

• Establish a size-constrained long in ARQT: 2–3% of portfolio now, scale to 4% if price retraces to $24 (≈20% below $30). Set a technical/valuation stop at $22 (≈27% drawdown) to limit tail loss while retaining upside to PDUFA.
• Buy a defined-risk call spread around the sNDA window: allocate 0.5–1.0% notional to a call spread that expires ~30–60 days after the June 29 PDUFA (e.g., buy-the-lower-strike / sell-a-higher-strike) to capture approval upside while capping premium outlay.
• Implement a relative-value hedge: long ARQT equal-dollar vs short XBI (or a bespoke small-cap biotech basket) sized at 1–2% net exposure to hedge sector volatility and isolate ARQT-specific execution on scripts and pediatric approval.
• If ARQT position >5% of any fund, trim to 2–3% and redeploy proceeds into top Suvretta adjacencies (BNTC/META/LEGN) or defensive healthcare names; concentration risk from a single biotech remains the largest portfolio-level hazard.